Regulation of TGF-β Family Signaling by Inhibitory Smads

Keiji Miyazawa[1] and Kohei Miyazono[2]

[1]Department of Biochemistry, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan

[2]Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan

Correspondence: miyazono@m.u-tokyo.ac.jp

Cold Spring Harbor Perspectives in Biology
www.cshperspectives.org

Inhibitory Smads (I-Smads) have conserved carboxy-terminal MH2 domains but highly divergent amino-terminal regions when compared with receptor-regulated Smads (R-Smads) and common-partner Smads (co-Smads). Smad6 preferentially inhibits Smad signaling initiated by the bone morphogenetic protein (BMP) type I receptors ALK-3 and ALK-6, whereas Smad7 inhibits both transforming growth factor β (TGF-β)- and BMP-induced Smad signaling. I-Smads also regulate some non-Smad signaling pathways. Here, we discuss the vertebrate I-Smads, their roles as inhibitors of Smad activation and regulators of receptor stability, as scaffolds for non-Smad signaling, and their possible roles in the nucleus. We also discuss the posttranslational modification of I-Smads, including phosphorylation, ubiquitylation, acetylation, and methylation.

Ligands of the transforming growth factor β (TGF-β) family play crucial roles in embryonic development and adult tissue homeostasis. The family includes TGF-βs, activins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), and Müllerian-inhibiting substance (MIS). These ligands are both structurally related to each other and share the basic machinery for signal transduction. TGF-β family ligands trigger signaling through hetero-oligomerization of two types of transmembrane receptors with intrinsic serine-threonine kinase activities: the type I and type II receptors (Shi and Massagué 2003). Five type II receptors and seven type I receptors, also called activin receptor-like kinase (ALK) 1–7, have been identified in mammalian cells. In the ligand–receptor complex, the constitutively active type II receptors phosphorylate and activate the type I receptors. The type I receptors then phosphorylate a subgroup of Smad proteins, the receptor-regulated Smads (R-Smads). The R-Smads comprise Smad2 and -3 for TGF-β and activin signaling, and Smad1, -5, and -8 for BMP signaling. Phosphorylated R-Smads form a heterotrimeric complex with a distinct common-partner Smad (co-Smad), Smad4. The complexes then translocate to the nucleus, where they activate or repress gene expression in association with other transcription factors and transcriptional coactivators or corepressors (the Smad signaling pathway). Alternatively, the ac-

Editors: Rik Derynck and Kohei Miyazono
Additional Perspectives on The Biology of the TGF-β Family available at www.cshperspectives.org

 doi: 10.1101/cshperspect.a022095
Cite this article as Cold Spring Harb Perspect Biol 2017;9:a022095

tivated receptors can transmit signals independent of Smad proteins (non-Smad signaling pathways) (Zhang 2009).

TGF-β family signaling is regulated through multiple mechanisms and its amplitude is finely tuned by a variety of positive and negative regulators (Miyazono 2000). Although negative signal regulators are found in other signaling pathways, the TGF-β family signaling systems may be unique, as some negative regulators are structurally related to the components of the signaling pathway. In addition, TGF-β family signaling induces the expression of many of these negative regulators in different types of cells, and these regulators, in turn, repress signaling through negative feedback loops. Lefty 1 and lefty 2 contain cystine-knot motifs and are structurally similar to the TGF-β family ligands, but do not form disulfide-linked dimers (Meno et al. 1999; Thisse and Thisse 1999). Lefty 1 and lefty 2 bind to activin receptors and compete with activins for receptor binding. Inhibins are dimeric proteins composed of an α- and β-chain, and antagonize the effects of activins composed of β-chain dimers (Vale et al. 1988). BAMBI (BMP and activin membrane-bound inhibitor) is a transmembrane protein with extracellular and transmembrane domains structurally similar to those type I receptors, but lacks an intracellular kinase domain (Onichtchouk et al. 1999). BAMBI interacts with type I receptors but is unable to transduce intracellular signals.

Inhibitory Smads (I-Smads) are members of the Smad family with conserved carboxy-terminal MH2 domains, which inhibit intracellular signaling through interactions with activated type I receptors and R-Smads. Smad6 preferentially inhibits Smad signaling by the BMP type I receptors ALK-3 and ALK-6 (Goto et al. 2007), whereas Smad7 inhibits both TGF-β- and BMP-induced Smad signaling (Hanyu et al. 2001). I-Smads also regulate certain non-Smad signaling pathways. Here, we focus on the mechanisms of action of I-Smads in TGF-β family signaling pathways in vertebrates and their relation to certain clinical diseases. We also discuss the functions of I-Smads that are independent of TGF-β family signaling.

STRUCTURES OF I-SMADS

Among the eight different Smad proteins in vertebrates, Smad6 and Smad7 are I-Smads (Hayashi et al. 1997; Imamura et al. 1997; Nakao et al. 1997; Hata et al. 1998; Souchelnytskyi et al. 1998). In *Drosophila*, daughters against DPP (Dad) acts as an I-Smad (Tsuneizumi et al. 1997; Inoue et al. 1998). In *Caenorhabditis elegans*, the TAG68 protein is structurally related to I-Smads, but has not yet been shown to function as an I-Smad (Padgett and Patterson 2006). The carboxy-terminal MH2 domains are conserved between I-Smads and other Smads, but the amino-terminal regions (N domains) of I-Smads diverge from the MH1 domains and linker regions of R-Smads and common-partner Smads (co-Smads) (Fig. 1). I-Smads inhibit TGF-β family signaling through multiple mechanisms, among which interactions with activated type I receptors and activated R-Smads are crucial for the inhibition of Smad-mediated signaling. The MH2 domains are required for interactions with activated type I receptors and R-Smads. R-Smads have an Ser-Ser-X-Ser (SSXS) motif at their carboxyl terminus, which is phosphorylated by type I receptors, whereas I-Smads and the co-Smad lack such a motif and are not phosphorylated by type I receptors.

Only a low level (36.7%) of amino acid sequence identity exists between the N domains of mouse Smad6 and Smad7. In addition, the N domains of Smad6 and Smad7 are not highly conserved between mammals and *Xenopus* (51.3% amino acid sequence identity in Smad6 and 67.4% in Smad7) (Nakayama et al. 1998a,b). A truncated form of Smad6 lacking 235 amino acid residues of the amino terminus is expressed in human endothelial cells (Topper et al. 1997). In this truncated protein (termed Smad6s), the long amino-terminal sequence of Smad6 is replaced with a unique 12 amino acid sequence followed by the carboxy-terminal half of wild-type Smad6. On injection of Smad6s RNA into *Xenopus* embryos, Smad6s antagonizes BMP signaling similarly to full-length Smad6 (Krishnan et al. 2001). Smad6s is expressed in the human coronary artery (Krishnan et al. 2001), with up-regulated expression in athero-



site; Ac/Ub, acetylation and ubiq-

which recruits the corepressor carboxy-terminal binding protein (CtBP) to Smad6 (Lin et al. 2003). The N domain of Smad7 also has a Leu-rich motif (LRM), which is required for recruitment of the E2 ubiquitin-conjugating enzyme UbcH7 (Ogunjimi et al. 2005). Although the LRM is partially conserved in Smad6, it is unknown whether the LRM of Smad6 interacts with UbcH7.

MECHANISMS UNDERLYING THE FUNCTIONS OF I-SMADS

I-Smads inhibit TGF-β family signaling through various mechanisms (Fig. 2), including interfering with the interactions between R-Smads and type I receptors, down-regulation of cell surface type I receptors in cooperation with other regulators, prevention of complex formation by R-Smads and co-Smads, and tran-



Figure 2. Regulation of transforming growth factor β (TGF-β) family signaling through I-Smad association with activated type I receptors. (*A*) Inhibitory Smads (I-Smads) inhibit TGF-β family signaling via interactions with type I receptors and compete with receptor-regulated Smads (R-Smads) for receptor activation. The N domain of Smad7 associates with the MH2 domain and facilitates the interaction with type I receptors. (*B*) Smad ubiquitin regulatory factors (Smurfs) and other E3 ubiquitin ligases induce the degradation of receptors through interactions with I-Smads. UbcH7 is recruited to the Smad7–Smurf2 complex. Salt-inducible kinase (SIK) cooperates with the complex, whereas ubiquitin-specific peptidase 15 (USP15) counteracts the Smad7–Smurf2 complex. (*C*) The growth arrest and DNA damage protein 34 (GADD34)–PP1c complex induces dephosphorylation of activated type I receptors through interactions with I-Smads. (*D*) Toll-interacting protein (Tollip) interacts with Smad7 and ubiquitylated type I receptor to facilitate the endosomal localization of receptors, possibly leading to their lysosomal degradation.

scriptional regulation in the nucleus. I-Smads also regulate non-Smad signaling pathways induced by TGF-β family proteins and control other signaling pathways and transcription factors that do not directly mediate TGF-β family signaling.

Inhibition of TGF-β Family Signaling through Direct Interaction with Type I Receptors

The MH2 domains of I-Smads associate directly with activated type I receptors and thus compete with R-Smads for activation by the receptors (Fig. 2A). The L3 loop in the MH2 domain of R-Smads plays an essential role in determining their specificity for binding type I receptors. Although the L3 loops in I-Smads do not provide binding specificity, they are indispensable for the association of I-Smads with type I receptors and cannot be replaced by the L3 loop of Smad4 (Kamiya et al. 2010). Smad7 uses two distinct protein surfaces in the MH2 domain, both of which include the L3 loop, for its interaction with type I receptors. One surface is the basic groove that includes the L3 loop and α-helix 1, which is also important in R-Smads for their binding specificity with type I receptors (Mochizuki et al. 2004). The other surface

is a three-finger-like structure consisting of residues 331–361, residues 379–387, and the L3 loop (Kamiya et al. 2010). Smad7 can use both surfaces in its interaction with the ALK-2, -3, and -4 receptors, but only the basic groove is used in the interaction between Smad7 and the TGF-β type I receptor (TβRI, also known as ALK-5). In contrast, Smad6 exclusively uses the basic groove in its interaction with the BMP type I receptor ALK-3.

Although the MH2 domains of I-Smads are required for interactions with type I receptors, the Smad7 MH2 domain is not sufficient for maximum inhibition of TGF-β signaling, and the N domain of Smad7 plays an important role in efficiently repressing TGF-β signaling. A chimeric protein composed of the N domain of Smad7 and the MH2 domain of Smad6 is as potent as wild-type Smad7 in inhibiting TGF-β signaling (Hanyu et al. 2001). The R-Smad MH1 domain may physically interact with the MH2 domain, interfering with the R-Smad association with type I receptors and complex formation with Smad4 (Hata et al. 1997). In contrast, the N domain of Smad7 physically associates with the MH2 domain and facilitates interactions between the MH2 domain and type I receptors (Hanyu et al. 2001; Nakayama et al. 2001).

Inhibition of TGF-β Family Signaling through Effector Recruitment to Type I Receptors

In addition to the direct inhibition of type I receptor kinase activity, I-Smads inhibit signaling in cooperation with other proteins by affecting the fate of type I receptors after activation.

BAMBI is a homolog of the type I receptors and functions as a general negative regulator of TGF-β family signaling by interfering with the formation of a functional complex by type I and type II receptors (Onichtchouk et al. 1999; Yan et al. 2009). In addition, through the formation of a ternary complex with Smad7 and the TβRI receptor, BAMBI suppresses the association of R-Smads with the receptors, blocking their phosphorylation. The inhibitory effect of Smad7 on TGF-β signaling is partially attenuated on silencing BAMBI expression and, conversely, that of BAMBI is partially attenuated on silencing Smad7 (Yan et al. 2009).

The HECT (homologous to the E6-accessory protein) type E3 ligases Smurf1 and Smurf2 physically interact with I-Smads and enhance their inhibition of TGF-β family signaling. Smurf1 and Smurf2 were originally identified as molecules that associate with and degrade R-Smads (Zhu et al. 1999; Lin et al. 2000; Zhang et al. 2001). The WW domains of Smurfs are involved in their interaction with the PY motifs of Smads (Zhu et al. 1999; Zhang et al. 2001). In addition to targeting R-Smads for degradation, leading to inhibition of TGF-β family signaling, Smurfs associate with Smad6 and Smad7 and assist in their association with type I receptors, interfering with the interactions between R-Smads and receptors (Fig. 2A) (Kavsak et al. 2000; Ebisawa et al. 2001; Murakami et al. 2003). Smurf1 has functional nuclear export signals in the HECT domain and facilitates the export of I-Smads from the nucleus to the cytoplasm in a CRM1-dependent fashion (Tajima et al. 2003). Moreover, Smurf1 has a C2 domain in its amino-terminal region that targets the Smurf1–Smad7 complex to the plasma membrane after nuclear export and enhances the interaction of Smad7 with the activated TβRI receptor (Suzuki et al. 2002). Such cooperative action of Smad6 and Smurf1 has been shown in vivo using transgenic mice expressing Smad6 and Smurf1 (Horiki et al. 2004). Although transgenic mice with increased expression of Smurf1 in chondrocytes do not show significant abnormalities, double-transgenic mice overexpressing Smad6 and Smurf1 in chondrocytes show a greater delay in endochondral ossification than Smad6 transgenic mice, suggesting that Smurf1 enhances the effects of Smad6 in vivo (Horiki et al. 2004).

In addition to promoting R-Smad degradation, Smurfs induce the ubiquitylation and proteasomal degradation of type I receptors and down-regulate the number of receptors at the cell surface, resulting in the suppression of TGF-β family signaling (Fig. 2B). Ubiquitylation is induced by an enzyme cascade, including activating (E1), conjugating (E2), and ligating (E3) enzymes. Smad7 facilitates the interaction be-

tween Smurf2 and the E2 enzyme UbcH7 (Ogunjimi et al. 2005). The N domain of Smad7 interacts with the HECT domain of Smurf2, as well as UbcH7 via its LRM sequence (see Figs. 1 and 2B). Thus, Smad7 regulates the function of Smurf2 by recruiting UbcH7 to the HECT domain and facilitates the degradation of type I receptors.

Salt-inducible kinase (SIK) is a serine-threonine kinase of the AMP-activated protein kinase family. SIK interacts and cooperates with the Smad7–Smurf2 complex, facilitating the down-regulation of activated TβRI receptor (Kowanetz et al. 2008; Lönn et al. 2012). The protein kinase activity of SIK enhances the down-regulation of TβRI by Smurf2, but the substrates involved in this pathway are unknown. SIK expression is induced by TGF-β and BMP signaling; thus, SIK functions as a negative feedback regulator.

In contrast, ubiquitin-specific peptidase 15 (USP15) is a deubiquitylating enzyme that counteracts the degradation of type I receptors by the complex of Smad7 and Smurf2 (Eichhorn et al. 2012). USP15 is recruited to the TβRI receptor by interacting with the Smad7–Smurf2 complex, then deubiquitylates and stabilizes TβRI. The *USP15* gene is amplified in glioblastoma, breast carcinoma, and ovarian carcinoma, and potentiates their malignant phenotypes by enhancing TGF-β signaling.

Some other HECT type E3 ligases, such as WWP1/Tiul1 and NEDD4-2, also inhibit TGF-β and BMP signaling by promoting the degradation of type I receptors (Komuro et al. 2004; Seo et al. 2004; Kuratomi et al. 2005). AIP4/Itch is another HECT type E3 ligase that interacts with Smad7. Interestingly, AIP4/Itch inhibits TGF-β signaling by enhancing the interaction of Smad7 with the TβRI receptor, but it does not induce the degradation of TβRI (Lallemand et al. 2005). However, AIP4/Itch has been reported to promote the ubiquitylation of Smad2 and enhance TGF-β-induced transcription (Bai et al. 2004), suggesting that AIP4/Itch may modulate TGF-β signaling in a context-dependent fashion.

Smad7 has also been shown to interact with IGADD34 (growth arrest and DNA damage protein 34), a regulatory subunit of the protein phosphatase 1 (PP1) holoenzyme that recruits the catalytic subunit of PP1 (PP1c) (Fig. 2C) (Shi et al. 2004). Smad7 facilitates dephosphorylation of the activated TβRI receptor through recruitment of the GADD34-PP1c complex. The expression of both GADD34 and Smad7 is induced by UV light irradiation, leading to TGF-β resistance in epithelial cells exposed to UV light. In endothelial cells, TGF-β activates both the TβRI/ALK-5 receptor and the ALK-1 receptor, a type I receptor that is activated by either TGF-β or BMP-9/10 and phosphorylates Smad1/5/8 (Goumans et al. 2003). By activating ALK-1, TGF-β induces the expression of Smad7 and PP1α, a mammalian isoform of PP1c, in endothelial cells. Smad7 then recruits PP1α to ALK-1 and attenuates the ALK-1-induced activation of Smad1 and 5 (Valdimarsdottir et al. 2006).

Toll-interacting protein (Tollip) is an adaptor protein that consists of a Tom1 binding domain (TBD), a C2 domain, and a coupling of ubiquitin to endoplasmic reticulum degradation (CUE) domain. Tollip interacts with the MH2 domain of Smad7 through its C2 domain. In response to TGF-β, and with the aid of Smad7, Tollip associates with the ubiquitylated TβRI receptor through its TBD and CUE domains, facilitating endosomal localization of TβRI (Fig. 2D). Tollip may promote the degradation of TβRI without affecting Smurf-mediated degradation (Zhu et al. 2012). Thus, Smad7 interacts with activated type I receptors and represses TGF-β family signaling through competition with R-Smads for receptor interaction, promoting proteasomal degradation of receptors by Smurfs, dephosphorylation of activated receptors by PP1, and facilitated endosomal localization by Tollip (Fig. 2).

Interference in R-Smad Complex Formation with Co-Smad

Smad6 interacts with activated Smad1 and inhibits BMP signaling by interfering with the formation of a complex between Smad1 and Smad4 (Hata et al. 1998). In addition, the association of Smurf1 with I-Smads can result in an

indirect association of Smurf1 with Smad1/5, leading to Smad1/5 ubiquitylation and degradation (Murakami et al. 2003). BMP stimulates the interaction of I-Smads with Smad1 and -5, which is further enhanced by Smurf1 (Hata et al. 1998; Murakami et al. 2003). Similarly, Smad7 can inhibit TGF-β signaling by targeting Smad2/3. Smad7 forms a heteromeric complex with activated Smad2/3 and interferes with Smad2/3–Smad4 complex formation. It also recruits the HECT-type E3 ligase NEDD4-2 to the Smad2/3–Smad7 heteromeric complex and facilitates the ubiquitylation and degradation of phosphorylated Smad2/3 (Yan et al. 2016). Consistently, a Smad7 mutant that fails to interact with TβRI still inhibits signaling induced by TGF-β (Kamiya et al. 2010).

Direct Transcriptional Regulation of TGF-β Family Signaling by I-Smads in the Nucleus

I-Smads are predominantly located in the nucleus in most cell types and can act as transcriptional regulators in the nucleus. Smad7 has been reported to interfere with the formation of functional Smad–DNA complex, with Smad7 interacting with the Smad-binding DNA element through its MH2 domain (Zhang et al. 2007). Smad7 fused to the DNA-binding domain of GAL4 represses Gal4 luciferase reporter genes (Pulaski et al. 2001; Yan et al. 2014), and this activity is enhanced in cooperation with YY1 and histone deacetylase 1 (HDAC-1) (Yan et al. 2014), suggesting that Smad7 acts as a transcriptional corepressor.

Smad6 interacts with the transcriptional corepressor CtBP through its PLDLS motif in the linker region (Fig. 1) (Lin et al. 2003). Because the PLDLS motif is not conserved in Smad7, only Smad6 can recruit CtBP. Smad6 possibly associates with the *Id1* promoter DNA through interactions with Smad1 and represses BMP-induced transcription of *Id1* in the nucleus. CtBP represses transcription in HDAC-dependent and -independent fashions depending on the promoter context. Whether the transcriptional repression of *Id1* by Smad6 is dependent on HDACs is unknown.

Smad6 also interacts with the homeobox transcription factors Hoxc-8 and -9 on BMP stimulation and inhibits the transcription of *osteopontin* (Bai et al. 2000). Smad6 interacts with some HDACs, including HDAC-1 and -3, through its MH2 domain. In addition, Smad6 has been reported to bind to DNA through its N domain and recruit HDACs to DNA (Bai and Cao 2002). The HDAC inhibitor trichostatin A abolishes the repressive effect of Smad6 on BMP signaling. Furthermore, Smad6 inhibits the interaction of Smad1 with Hoxc-8 and suppresses transcription by Smad1.

Roles of I-Smads in Non-Smad Signaling Pathways

In addition to the Smad pathway, TGF-β can transmit signals through non-Smad pathways, many of which still remain to be elucidated in detail. Among these, the TRAF6 (tumor necrosis factor [TNF] receptor-associated factor 6) adaptor protein leads to activation of p38 mitogen activated kinase (MAPK) and c-Jun amino-terminal kinase (JNK) signaling (Sorrentino et al. 2008; Yamashita et al. 2008). Smad6 and Smad7 have been shown to play distinct roles in their activation.

In response to TGF-β, TRAF6 associates with the heterotetrameric TGF-β receptor complex through its TRAF homology domain. TRAF6 then induces K63-linked polyubiquitylation of itself, as well as TAK1 (TGF-β activated kinase 1), which is recruited to the TβRI receptor by Smad7. TAK1 is a MAPKKK activated in response to TGF-β, interleukin-1, and several other inducers (Yamaguchi et al. 1995; Ninomiya-Tsuji et al. 1999; Shim et al. 2005). K63-linked polyubiquitylation activates TAK1, which triggers the activation of p38 MAPK or JNK by MAP kinase kinase 3 (MKK3) or MKK6, inducing apoptosis (Edlund et al. 2003) or actin reorganization through activation of small GTPases Cdc42 and RhoA (Edlund et al. 2004). Smad7 is required for the TRAF6 pathway, as its scaffold function allows assembly of TAK1, MKK3, and p38 MAPK, and facilitates the activation of p38 MAPK (Edlund et al. 2003; Jung et al. 2013).

In contrast, Smad6 negatively regulates the TRAF6 pathway (Jung et al. 2013). TGF-β induces the expression of Smad6 through Smad-mediated transcriptional activation (Afrakhte et al. 1998). Smad6 then associates with TRAF6 and the TNF-α-induced protein A20 (Krikos et al. 1992) via distinct regions of the protein. A20 inhibits several ubiquitin ligases, including TRAF6, and functions as a negative regulator of the NF-κB pathway. Smad6 suppresses the activation of p38 MAPK and JNK by facilitating the inhibition of TRAF6 by A20 (Jung et al. 2013).

Thus, Smad7 effectively enhances the TGF-β-induced noncanonical TRAF6-p38-JNK pathway, acting as a scaffold to facilitate TAK1-mediated activation of downstream kinases and also inhibiting the induction of Smad6 expression through suppression of the Smad pathway. These findings explain previous reports that increased Smad7 expression leads to the apoptosis of some epithelial cell lines (Landström et al. 2000; Lallemand et al. 2001; Mazars et al. 2001), probably because of increased TRAF6 pathway activity.

Regulation of Other Signaling Pathways by I-Smads

TGF-β has anti-inflammatory activity that is mediated through the induction of I-Smads. Specifically, Smad7 aids in the inhibition of proinflammatory TNF-α signaling (Lallemand et al. 2001). The TNF receptor 1 signals through TRAF2, which activates TAK1 in the presence of TAB2 and TAB3, but Smad7 sequesters TAB2 and TAB3, inhibiting the activation of TAK1 and downstream NF-κB (Hong et al. 2007). Accordingly, Smad7 induces apoptosis in podocytes through inhibition of NF-κB signaling (Schiffer et al. 2001).

Smad6 also suppresses innate immunity responses. Toll-like receptors (TLRs) are involved in innate immunity by excluding invading pathogens. Among the TLRs, TLR4 and TLR2 signal through MyD88 to induce the activation of NF-κB. TGF-β inhibits the MyD88-dependent pathway by inducing Smad6 expression. Smad6 then recruits Smurfs to MyD88 and triggers its polyubiquitylation and proteasomal degradation (Lee et al. 2011). In addition, Smad6 sequesters Pellino, an adaptor protein that interacts with interleukin-1 receptor-associated kinase 1 (IRAK1) and interferes with the formation of the IRAK1-mediated signaling complex downstream of MyD88 in the TLR4 signaling pathway (Choi et al. 2006). A subregion of the Smad6 MH2 domain spanning amino acid residues 422–441 is responsible for the association with Pellino. Smaducin-6, a palmitic acid-conjugated peptide containing the Pellino-binding sequence, is therapeutically effective in cecal ligation puncture-induced sepsis, a mouse model of TLR4-mediated inflammatory disease (Lee et al. 2015).

Wnt proteins transmit signals through glycogen synthase kinase 3β (GSK-3β) and stabilize β-catenin. The expression of c-myc and other genes is induced by complexes of β-catenin with one of the related transcription factors, lymphoid enhancer-binding factor 1 (LEF1) or T-cell factor (TCF). Smad7 has also been shown to interact with β-catenin and LEF1 or TCF in response to TGF-β stimulation, and to induce β-catenin accumulation in a p38 MAPK-dependent manner (Edlund et al. 2005). Thus, the induction of c-myc expression by β-catenin may contribute, at least in part, to the induction of apoptosis by Smad7. Smad7 is also required for the TGF-β-induced phosphorylation of Akt and GSK-3β (Edlund et al. 2005). Thus, Smad7 appears to function as a scaffold protein for direct activation of p38 MAPK and other signaling pathways. However, Smad7 inhibits apoptosis by suppressing TGF-β signaling in some cells (Yamamura et al. 2000; Arnold et al. 2004), suggesting that these signaling pathways may be activated by Smad7 in cell-type-specific and context-dependent fashion. Smad6 plays an important role in promoting the exit of neuronal progenitor cells from the cell cycle and inducing neuronal differentiation in the developing chick dorsal spinal cord, where Smad6 recruits CtBP to the β-catenin/TCF complex, suppressing the Wnt/β-catenin pathway (Xie et al. 2011).

Smad7, but not Smad6, has been shown to interact through its MH2 domain with c-Cbl in keratinocytes (Ha Thi et al. 2015). Smad7

destabilizes epidermal growth factor (EGF)-induced complex formation between c-Cbl and the epidermal growth factor receptor (EGFR), inhibiting ligand-induced ubiquitylation and degradation of EGFR (Ha Thi et al. 2015). These observations are in contrast to the enhanced EGFR signaling in *Smad7*$^{\Delta exI}$ mice (Krampert et al. 2010), suggesting multiple and complex functions of Smad7 in the regulation of EGFR signaling.

Smad7 can also directly interact with other transcription factors and regulate their stability and/or function. Smad7 promotes skeletal muscle differentiation through association with MyoD, a master regulator of myogenic differentiation, and enhances its transcriptional activity (Kollias et al. 2006) by protecting it from repression by MEK (Miyake et al. 2010). In turn, MyoD binds to the *Smad7* proximal promoter region and induces its expression. Thus, Smad7 and MyoD form a positive feedback loop to drive myogenic differentiation (Kollias et al. 2006). When Smad7 interacts with interferon regulatory factor 1 (IRF1), it increases the affinity of this transcription factor for the interferon-stimulated response element (ISRE) DNA sequence, regulating the cell death pathway by enhancing the expression of target genes, including the gene encoding caspase 8 (Hong et al. 2013). Smad7 also interacts with c-Myc, but it induces the down-regulation of c-Myc protein via ubiquitylation-mediated proteolysis on recruitment of the F-box protein Skp2, leading to cytostasis (Kim et al. 2014).

Smad6 interacts with the glucocorticoid receptor and represses the transactivation induced by glucocorticoid receptor through recruitment of HDAC-3 (Ichijo et al. 2005). Smad6 also cooperates with Smurf1 in the degradation of Runx2 (Shen et al. 2006). Although Smad6 functions in many cases as a transcriptional repressor, it appears to enhance the expression of osteopontin, Hex, and Id2 during macrophage differentiation by binding to their promoter regions either directly or indirectly (Glesne and Huberman 2006). During macrophage differentiation, Smad6 is phosphorylated at Ser435 by protein kinase X, which may regulate the nuclear function of Smad6 (Glesne and Huberman 2006).

CONTROL OF I-SMAD FUNCTIONS BY POSTTRANSLATIONAL MODIFICATIONS AND PROTEIN INTERACTIONS

The functions of I-Smads are regulated by posttranslational modifications and interactions with other proteins, which in turn control their stability and association with receptors (Fig. 3).

Regulation of I-Smad Protein Stability

Multiple proteins, including ubiquitin ligases, promote or enhance TGF-β family signaling by inducing degradation of I-Smads in cooperation with accessory molecules. Smad7 is ubiquitylated at Lys64 and Lys70. These lysines are also acetylated by the acetyltransferase p300 (Grönroos et al. 2002), conferring resistance to ubiquitylation. In addition, Smad7 interacts with HDACs, associating with class I HDACs (HDAC-1 and -3) and class II HDACs (HDAC-5 and -6) through its MH2 domain (Simonsson et al. 2005), and with the class III HDAC sirtuin 1 (SIRT1) through its N domain (Kume et al. 2007). HDAC-1 and SIRT1 deacetylate Smad7 and facilitate its ubiquitylation. Thus, modification of Smad7 by acetylation, deacetylation, and ubiquitylation determines its stability. TGF-β signaling inhibits the acetylation of Smad7, although the interaction between Smad7 and HDACs occurs independently of TGF-β signaling (Grönroos et al. 2002; Simonsson et al. 2005). The regulatory mechanisms for these modifications to Smad7 remain to be elucidated.

Arkadia (also known as RNF111), a RING type E3 ubiquitin ligase, was first identified as a protein that enhances signaling by Nodal, inducing the Spemann's organizer during early embryogenesis (Episkopou et al. 2001; Niederlander et al. 2001). Arkadia controls the amplification of TGF-β family signaling through interactions with I-Smads. In contrast to Smurfs, Arkadia induces ubiquitin-dependent degradation of Smad6 and Smad7 but not of the type I receptors, leading to enhanced TGF-β family signaling (Koinuma et al. 2003; Tsubakihara et al. 2015). The enhancement of Smad signal-



ing by Arkadia is also attributed to its ability to down-regulate c-Ski and SnoN, which suppresses Smad signaling in the nucleus (Levy et al. 2007; Nagano et al. 2007; Le Scolan et al. 2008). The association of Arkadia with Smad7, but not c-Ski or SnoN, is enhanced in the presence of Axin (Liu et al. 2006; Koinuma et al. 2011), a scaffold protein that assembles APC, GSK-3β, and casein kinase Iα, and regulates Wnt signaling through degradation of β-catenin. Axin forms a ternary complex with Smad7 and Arkadia to facilitate the degradation of Smad7 (Liu et al. 2006). Similarly, the association of Arkadia with c-Ski, but not Smad7 nor SnoN, is enhanced in the presence of RB1CC1 (RB1-inducible coiled-coil 1, also known as FIP200) (Koinuma et al. 2011). Thus, Arkadia appears to require accessory proteins to preferentially target regulators of Smad signaling.

Screening ubiquitin ligases that regulate TGF-β signaling using a small interfering RNA (siRNA) library showed that, in addition to Arkadia (Levy et al. 2007), RING-H2 finger protein 12 (RNF12) also enhances TGF-β family signaling through ubiquitin-dependent degradation of Smad7 (Zhang et al. 2012). Furthermore, the nuclear receptor NR4A1 interacts with Axin2 and Smad7, facilitating ubiquitylation of Smad7 in cooperation with Arkadia or RNF12, and strongly enhancing TGF-β signaling (Zhou et al. 2014).

Jab1/CSN5 is a component of the COP9 signalosome complex involved in protein degradation through the ubiquitin-proteasome pathway. Jab1/CSN5 interacts with and translocates Smad7 from the nucleus to the cytoplasm, facilitating its degradation (Kim et al. 2004a). However, Jab1/CSN5 also inhibits

TGF-β-induced Smad signaling by inducing the degradation of Smad4 (Wan et al. 2002), suggesting that Jab1/CSN5 may positively or negatively regulate TGF-β family signaling through the degradation of Smad7 and/or Smad4.

Cbl-b is a RING type E3 ubiquitin ligase highly expressed in T cells that inhibits T-cell activation. *Cblb*$^{-/-}$ mice develop spontaneous autoimmunity (Bachmaier et al. 2000), and CD4^{+}CD25^{-}Foxp3^{-} effector T cells from *Cblb*$^{-/-}$ mice do not efficiently convert into Foxp3^{+} regulatory T cells in response to TGF-β in vitro (Wohlfert et al. 2006). Subsequently, Cbl-b was shown to interact with and ubiquitylate Smad7, leading to decreased Smad7 levels and efficient TGF-β signaling in T cells (Gruber et al. 2013). Consistent with these findings, the repression of interleukin-2 and interferon-γ expression by TGF-β was attenuated in T cells prepared from *Cblb*$^{-/-}$ mice, but restored in those prepared from *Cblb*$^{-/-}$/*CD4Cre-Smad7*$^{fl/fl}$ mice (Gruber et al. 2013).

Hydrogen peroxide–inducible clone-5 (Hic-5), an adaptor protein containing LIM domains, interacts with Smad7 and induces its down-regulation (Wang et al. 2008), which is not inhibited by proteasomal inhibitors. Because Hic-5 also associates with Smad3 and inhibits Smad3-dependent transcription (Wang et al. 2005), it may preferentially enhance Smad2-dependent and non-Smad signaling through targeted degradation of Smad7 (Wang et al. 2008).

Regulation of the Interaction between I-Smads and Type I Receptors

Smad6 is methylated at Arg38 by protein arginine *N*-methyltransferase 1 (PRMT1) (Inamitsu et al. 2006; Xu et al. 2013). The methylation is facilitated in the BMP-induced receptor complex; PRMT1 associates with the type II receptor while Smad6 interacts with the type I receptor (Xu et al. 2013). The resultant methylation of Smad6 in response to BMP leads to its dissociation from the type I receptor, permitting efficient signal transduction through phosphorylation of Smad1, -5, and -8. This reaction, a prerequisite for BMP signaling, partly explains the slow kinetics of Smad phosphorylation after BMP stimulation.

The UBE2O (ubiquitin-conjugating enzyme E2O, also known as E2-230K), which functions as an E2-E3 hybrid ubiquitin ligase, was identified as an I-Smad-binding protein in a proteomics screening (Zhang et al. 2013b). UBE2O interacts with and monoubiquitylates Smad6 at Lys174, reducing the interaction between Smad6 and BMP type I receptors. Thus, UBE2O promotes BMP signaling by suppressing Smad6 function. UBE2O also interacts with Arkadia and RNF12, recruiting these proteins to Smad7 and facilitating the polyubiquitylation of Smad7 (Zhang et al. 2013b). The contribution of this mechanism to TGF-β family signaling is yet to be examined.

Smad7 is phosphorylated at Thr96 by the murine protein serine/threonine kinase 38 (MPK38), which results in the translocation of Smad7 from the nucleus to the cytoplasm, enhancing the inhibitory activity of Smad7 at the TβRI receptor (Seong et al. 2010). Similarly, Smad6 is phosphorylated at Thr176 by MPK38, enhancing the inhibition of BMP signaling by Smad6 (Seong et al. 2010). In contrast, phosphorylation of Smad7 at Ser249 by other unknown kinase(s) does not significantly affect the inhibitory activity of Smad7 on TGF-β signaling (Pulaski et al. 2001).

Another protein, AMSH (associated molecule with the SH3 domain of STAM), binds Smad6 on BMP stimulation and antagonizes the inhibitory effects of Smad6 by preventing the interaction of Smad6 with BMP type I receptors and Smad1 (Itoh et al. 2001). In response to BMP-7 stimulation, Smad6 is exported to the cytoplasm and colocalizes with AMSH. BMP signaling induces the phosphorylation of AMSH by JNK and/or p38 MAPK, leading to attenuation of the antagonistic effects of AMSH on Smad6 function (Itoh et al. 2001). AMSH2, an AMSH-related protein, also interacts with Smad7 and suppresses its inhibitory activity (Ibarrola et al. 2004). The activity of AMSH is regulated by RNF11, a small RING finger protein that interacts with Smurf2 and AMSH (Li and Seth 2004). The RNF11–Smurf2

complex induces ubiquitin-dependent degradation of AMSH, resulting in the inhibition of TGF-β family signaling in RNF11- and Smurf2-expressing cells. AMSH belongs to a family of deubiquitylating enzymes, but whether the deubiquitylation activity is required for its inhibitory action on I-Smads is unclear.

Tob (transducer of ErbB2) is a member of the "antiproliferative protein" family, which also includes Tob2, BTG1, BTG2/PC3/TIS21, and BTG3. Tob associates with Smad1, -5, and -8, and represses BMP-dependent transcription in osteoblasts (Yoshida et al. 2000). In addition, Tob and Tob2 interact with I-Smads and attenuate BMP signaling by enhancing the interaction of I-Smads with activated BMP type I receptors at the plasma membrane (Yoshida et al. 2003). Similarly, YAP65 and STRAP interact with Smad7, facilitate its association with activated type I receptors, and augment its inhibitory activity (Datta and Moses 2000; Ferrigno et al. 2002).

TGF-β-stimulated clone 22 (TSC-22), a protein with a conserved TSC box and a leucine zipper motif, interferes with the association of the Smad7–Smurf complex with TβRI, preventing ubiquitylation-dependent receptor degradation (Yan et al. 2011). Because TSC-22 is posttranscriptionally up-regulated by TGF-β, it is a positive feedback regulator of TGF-β signaling.

CONTROL OF I-SMAD EXPRESSION

The expression of I-Smads is regulated in response to a variety of stimuli, including TGF-β, BMP, interferon-γ, cytokines that activate NF-κB signaling, laminar shear stress, and UV irradiation. In response to TGF-β, the Smad3–Smad4 complex associates with the *Smad7* promoter and activates its transcription, whereas BMP induces Smad1 to bind and activate *Smad7* transcription through distinct regulatory elements (Nagarajan et al. 1999; Denissova et al. 2000; Benchabane and Wrana 2003). The transcription factors AP-1, TFE3, and Sp1 also bind to the *Smad7* promoter and regulate its transcription (Brodin et al. 2000; Hua et al. 2000), and GATA transcription factors cooperate with Smad1 in BMP-induced *Smad7* expression (Benchabane and Wrana 2003). Conceptually similarly, Smad1 and -5 associate with the *Smad6* promoter in response to BMP and induce its transcription (Ishida et al. 2000). OAZ, a transcription factor with 30 Krüppel-like zinc fingers (Hata et al. 2000), interacts with Smad1 and induces BMP-dependent transcription of *Smad6* by binding to its promoter (Ku et al. 2006).

Under certain conditions, I-Smads enable signaling cross talk. In some cells, interferon-γ and interleukin-6 repress TGF-β family signaling through the induction of Smad7 expression by the Jak-STAT pathway (Ulloa et al. 1999; Jenkins et al. 2005). Interleukin-7 activates Smad7 expression and inhibits TGF-β signaling in fibroblasts derived from pulmonary fibrosis induced by bleomycin (Huang et al. 2002). Norepinephrine and the proinflammatory cytokines TNF-α and interleukin-1 induce Smad7 expression in an NF-κB-dependent manner (Bitzer et al. 2000; Kanamaru et al. 2001). The transmembrane protein CD40, which is structurally related to the TNF receptor family, also induces the expression of Smad7 through the NF-κB pathway (Patil et al. 2000).

$CD4^+CD25^+$ regulatory T cells play a crucial role in maintaining immunological self-tolerance. TGF-β induces a regulatory phenotype in human and mouse $CD4^+CD25^-$ T cells through the expression of the winged-helix/forkhead transcription factor Foxp3. Foxp3 efficiently suppresses the expression of Smad7 (Fig. 3), leading to enhanced TGF-β signaling and acquisition of regulatory properties by these cells, including an antiproliferative effect on $CD4^+$ T cells (Fantini et al. 2004). Thus, a positive autoregulatory loop of TGF-β signaling is formed in $CD4^+CD25^-$ T cells through Foxp3-mediated attenuation of Smad7 expression.

TGF-β signaling rapidly induces the expression of TIEG1 (TGF-β-inducible early gene-1), a Krüppel-like transcription factor. TIEG1 directly associates with the *Smad7* promoter and represses its expression, thereby enhancing TGF-β signaling (Johnsen et al. 2002a). Thus, TIEG1 forms a positive feedback loop of TGF-β signaling similar to Foxp3. The E3 ubiquitin

ligase SIAH1 (seven in absentia homolog 1A) associates with TIEG1 and induces its ubiquitylation and degradation, relieving the suppression of Smad7 expression (Johnsen et al. 2002b).

c-Ski and SnoN repress the basal transcription of *Smad7* by binding to the Smad-binding sequence of the *Smad7* promoter through Smad4 (Denissova and Liu 2004; Briones-Orta et al. 2006). However, on TGF-β stimulation, these repressive complexes dissociate from the *Smad7* promoter region, permitting induction of *Smad7* expression by the activated Smad3–Smad4 complex.

During osteoblast differentiation, the expression of I-Smads is strongly induced by BMP signaling in a biphasic manner; Smad6 and Smad7 expression are transiently induced by BMP within a few hours, and then later induced during osteoblast maturation (Maeda et al. 2004). Endogenous TGF-β also promotes the expression of I-Smads during osteoblast maturation, and the ALK-5/TβRI kinase inhibitor SB431542 represses endogenous TGF-β signaling and, thus, the induction of I-Smad expression. Consequently, inhibition of TGF-β signaling by SB431542 facilitates mesenchymal stem cell differentiation into osteoblasts in the maturation phase (Maeda et al. 2004).

Smad6 and Smad7 expression is detected in human vascular endothelium in vivo. Because Smad6 and Smad7 are induced by laminar shear stress, they may modulate the gene expression induced by TGF-β and BMPs in response to humoral and mechanical stimulation, respectively, in the vasculature in homeostasis and disease (Topper et al. 1997).

MicroRNA-21 (miR-21) is a TGF-β- and BMP-regulated miRNA. Activated Smad proteins promote the maturation of miR-21 independent of Smad4 by associating with the stem region of pri-miR-21 (Davis et al. 2008). Interestingly, miR-21 suppresses the expression of Smad7 protein in pulmonary fibroblasts (Liu et al. 2010), and appears to inhibit Smad7 messenger RNA (mRNA) translation while not affecting the Smad7 mRNA level (Li et al. 2013). In contrast, many microRNAs, including miR-181 and the miR-106b-25 and miR-216a/217 clusters, suppress Smad7 expression by inducing Smad7 mRNA degradation (Smith et al. 2012; Xia et al. 2013; Parikh et al. 2014), enhancing TGF-β signaling. miRNAs that control the expression of Smad6 have not yet been reported.

Several low molecular weight compounds regulate the expression of I-Smads, affecting TGF-β signaling. Simvastatin inhibits Smad6 and Smad7 expression in $CD4^{+}Foxp3^{-}$ T cells to promote the induction of $Foxp3^{+}$ cells by TGF-β (Kim et al. 2010). In contrast, halofuginone induces Smad7 mRNA expression (Xavier et al. 2004). How these low molecular weight compounds affect the expression of I-Smads remains to be elucidated.

IN VIVO FUNCTIONS OF I-SMADS

Smad6

Smad6 is expressed in the heart and blood vessels, and $Smad6^{-/-}$ mice show multiple cardiovascular abnormalities (Galvin et al. 2000), including defects in outflow tract septation and hyperplasia of the cardiac valves. These findings indicate important roles of Smad6 in the regulation of endocardial cushion transformation. Ossification of the outflow tracts of the heart and elevated blood pressure have also been observed in these mice. These findings are consistent with the role of Smad6 in repressing BMP signaling during normal development of the heart valves and outflow tract (Kruithof et al. 2012). Intriguingly, two nonsynonymous mutations that affect the inhibitory activity of Smad6 have been found in patients with cardiovascular malformation accompanying aortic stenosis (Tan et al. 2012). These mutations are located at evolutionarily conserved positions in the MH2 domain. The Smad6 C484F mutant has minimal inhibitory activity in BMP signaling, whereas the P415L mutant is hypomorphic. These findings reveal a critical role of Smad6 in cardiovascular organogenesis.

BMP signaling is also involved in the regulation of endochondral bone formation at multiple stages; it stimulates the proliferation of chondrocytes, but slows their hypertrophic differentiation (Minina et al. 2001; Valcourt

et al. 2002). *Smad6*$^{-/-}$ mice show craniofacial, axial, and appendicular skeletal abnormalities because of stage-specific defects in endochondral bone formation (Estrada et al. 2011) that can be attributed to enhanced BMP signaling in chondrocytes. Consistent with these findings, transgenic mice that express Smad6 in chondrocytes show dwarfism with osteopenia, delayed chondrocyte hypertrophy, and thin trabecular bone (Horiki et al. 2004).

Smad7

The phenotypes of *Smad7* mutant mice have been reported by several groups (reviewed in Beppu 2013). Some of the phenotypes can be explained by increased TGF-β or BMP activity, but others suggest that Smad7 functions independent of TGF-β family signaling. The first reported *Smad7* mutant mice lack the coding region in exon 1 and only partially lose Smad7 functions (Li et al. 2006). These *Smad7*$^{\Delta exI}$ mice with a hypomorphic allele are smaller than wild-type mice, but are viable and fertile. The smaller body size of *Smad7*$^{\Delta exI}$ mice appears to be due largely to attenuated differentiation of bone and skeletal muscle (Estrada et al. 2013; Cohen et al. 2015).

As with *Smad6*$^{-/-}$ mice, *Smad7*$^{\Delta exI}$ mice show abnormalities in axial and appendicular skeletal development (Estrada et al. 2013). Low Smad7 activity results in impaired cell cycle progression in chondrocytes and defects in terminal maturation, which can be attributed to enhanced BMP and TGF-β signaling in the growth plates. Both *Smad6* mutant mice and *Smad7* mutant mice show anterior and posterior transformations, indicating that they have overlapping functions. However, *Smad7* mutant mice have defects in lumbar patterning, whereas *Smad6*$^{-/-}$ mice do not, suggesting a unique function of Smad7.

The decreased muscle mass observed in *Smad7*$^{\Delta exI}$ mice can be attributed to enhanced myostatin (also known as GDF-8) signaling (Cohen et al. 2015). Myostatin is a member of the TGF-β family that potently suppresses skeletal muscle growth (Lee 2004) and decreases the transcriptional activity of MyoD in the absence of Smad7 (Kollias et al. 2006). *Smad7*$^{\Delta exI}$ mice also show altered myofiber type composition toward oxidative types, impaired skeletal muscle regeneration, and decreased satellite cell proliferation, probably as a result of enhanced myostatin signaling (Cohen et al. 2015).

TGF-β is a potent inducer of tissue fibrosis. In the CCl_4-induced chronic liver damage model, *Smad7*$^{\Delta exI}$ mice show more severe liver injury, elevated collagen deposition, and increased numbers of activated hepatic stellate cells (Hamzavi et al. 2008) compared with control mice. The mutant mice also show enhanced tissue injury, more progressive fibrosis, inflammation in a unilateral ureteral obstruction (UUO) model of renal fibrosis (Chung et al. 2009), streptozotocin-induced model of diabetic kidney injury (Chen et al. 2011), and angiotensin II-induced hypertensive nephropathy and cardiac remodeling (Liu et al. 2013; Wei et al. 2013). Enhanced inflammation in *Smad7* mutant mice may be attributed, at least in part, to the inhibitory effect of Smad7 on NF-κB signaling. Mutant B lymphocytes also show phenotypes with enhanced TGF-β signaling: facilitated class switch recombination to IgA, enhanced spontaneous apoptosis, and attenuated proliferation after stimulation with lipopolysaccharide (Li et al. 2006).

Intriguingly, *Smad7*$^{\Delta exI}$ mice are more susceptible to diethylnitrosoamine-induced hepatocarcinogenesis, suggesting that Smad7 has a tumor suppressor function in the liver (Wang et al. 2013). In addition, enhanced cell proliferation and suppressed apoptosis have been observed in the mutant mice. The phenotypes may be caused by derepression of *c-Myc* expression, enhanced NF-κB signaling, and/or attenuation of the TRAF6 pathway of TGF-β signaling.

Smad7$^{\Delta/\Delta}$ mutant mice, which lack expression of the entire Smad7 protein, are embryonic lethal (Kleiter et al. 2010). Furthermore, *Smad7*$^{\Delta MH2}$ mice on a C57BL/6 background, which lack the MH2 domain required for the inhibitory activity of Smad7, die before weaning (Chen et al. 2009; Tojo et al. 2012). *Smad7*$^{\Delta MH2}$ mice that die in utero have cardiac defects, including ventricular septal defects, noncompaction, and outflow tract malformation (Chen

et al. 2009). These phenotypes do not overlap with those of *Smad6*$^{-/-}$ mice (Galvin et al. 2000), suggesting functional specificity of each I-Smad in the cardiac system. Unexpectedly, the induction of TGF-β or BMP target genes, such as the genes encoding plasminogen activator inhibitor-1 or Id1, respectively, is not enhanced in mouse embryonic fibroblasts prepared from *Smad7*$^{\Delta MH2}$ embryos on the C57BL/6 background (Tojo et al. 2012) compared with cells from different organs in other reports (Kleiter et al. 2010; Zhu et al. 2011; Estrada et al. 2013). In addition, *Smad7*$^{\Delta MH2}$ mice with an internal control region (ICR) genetic background develop to adulthood, although their body size is smaller (Tojo et al. 2012). Thus, the phenotypic effects of *Smad7* inactivation are largely dependent on the context of the cells or organs.

High expression of Smad7 is observed in peripheral CD4^{+} cells from multiple sclerosis patients during relapse (Kleiter et al. 2010). The expression of Smad7 correlates positively with that of T-bet, a transcription factor involved in T helper cell type 1 (T_H1) responses. Consistent with these observations, transgenic mice with increased Smad7 expression in T cells (*CD2-Smad7*) show enhanced experimental autoimmune encephalomyelitis, a model of multiple sclerosis in which the infiltration of inflammatory cells and T_H1 responses are facilitated in the central nervous system. In contrast, T-cell-specific *Smad7* knockout in *CD4Cre-Smad7*$^{fl/fl}$ mice results in immunosuppression and reduced T_H1 responses, with unaltered T_H17 responses. The Smad7 expression level in T cells has been shown to be a determinant of T_H1 differentiation (Kleiter et al. 2010).

Smad7 is expressed in the lens and retina during embryonic eye development in mice, where BMP signaling has been shown to play important roles in lens induction, optic vesicle invagination, and retinal spatial patterning (Zhang et al. 2013a). *Smad7*$^{\Delta MH2}$ mice have multiple defects in eye development, including coloboma and microphthalmia. The effects of *Smad7* inactivation during eye development depend on the cell type, developmental stage, and genetic background of the mice. These phenotypes observed in mutant mice with the C57BL/6 background are rarely seen in mice with the 129/FVB hybrid background. In addition, enhanced apoptosis in the retina of *Smad7*$^{\Delta MH2}$ mice has been observed at E10.5 (Zhang et al. 2013a), whereas conditional inactivation of *Smad7* in developing neural retina (*αCre-Smad7*$^{fl/fl}$) has been shown to attenuate apoptosis at E16.5 and later, in which TGF-β signaling protects against developmental cell death through the induction of nerve growth factor (NGF) expression (Braunger et al. 2013).

Hepatocyte-specific deletion of the Smad7 MH2 domain using *albumin-Cre* transgenic mice results in spontaneous liver dysfunction with the apoptosis of hepatocytes and aggravation of alcohol-induced liver injury because of the down-regulation of alcohol dehydrogenase 1 (ADH1) expression (Zhu et al. 2011). Spontaneous liver damage is not observed in hypomorphic *Smad7*$^{\Delta exI}$ mice (Hamzavi et al. 2008), probably because of incomplete inactivation of Smad7 activity. Conditional silencing of *Smad7* in the pancreas at E10.5 (*PdxCre-ERT-Smad7*$^{fx/fx}$) results in a diminished number of hormone-producing cells, whereas genetic ablation of both Smad2 and Smad3 expression has effects that are opposite to those of Smad7 (El-Gohary et al. 2013). These phenotypes are explained by increased TGF-β signaling.

Smad7 may function independently from TGF-β and BMP signaling in certain situations. The proliferation of adult neural stem/progenitor cells is normally inhibited by TGF-β in vitro and in vivo (Wachs et al. 2006). However, the cells derived from *Smad7*$^{\Delta exI}$ mice have higher potential to proliferate, form spheres, and self-renew compared with cells from wild-type mice as a result of enhanced EGF signaling (Krampert et al. 2010). Another example is promotion of pancreas β-cell proliferation during inflammation induced by pancreatic duct ligation (PDL) (Xiao et al. 2014). After PDL, infiltrated M2 macrophages secrete TGF-β1, which induces Smad7 in β cells. Smad7 then promotes the proliferation of β cells by inducing the expression of cyclin D1 and D2 and excluding p27^{Kip1} from the nucleus. Increased Smad7 expression is required and sufficient for β-cell proliferation. The effect of Smad7 does not appear to

be caused by inhibition of TGF-β signaling, as conditional deletion of both TGF-β type I and II receptors in β cells substantially inhibits β-cell proliferation after PDL (El-Gohary et al. 2014).

DYSREGULATION OF I-SMADS IN DISEASE

Fibrosis

Decreased expression or deficient function of Smad7 leading to the acceleration of TGF-β-induced fibrosis has been reported in various diseases, including those of the skin, kidney, and lung. Smad7 expression is higher in scleroderma fibroblasts than in normal fibroblasts, but the inhibitory effect of Smad7 on TGF-β signaling is impaired in scleroderma fibroblasts (Asano et al. 2004). The expression levels of Smurfs do not differ significantly between normal and scleroderma cells (Asano et al. 2004), and the mechanisms underlying the impaired negative regulation of TGF-β signaling by the Smad7-Smurf system remain to be elucidated.

Although the Smad7 mRNA level is increased, a significant decrease in Smad7 protein has been observed in obstructive nephropathy in mice with UUO as a result of increased ubiquitylation and degradation of Smad7 (Fukasawa et al. 2004). Although the expression of Smurf1 and Smurf2 is increased in UUO kidneys, how Smad7 protein expression is reduced is unknown.

Consistent with the finding that TGF-β signaling plays important roles in the development of tissue fibrosis, adenovirus-mediated expression of *Smad7* attenuates TGF-β-induced fibrosis in various tissues, including the lung and kidney (Nakao et al. 1999; Terada et al. 2002). In addition, adenoviral expression of *Smad7* prevents the epithelial-mesenchymal transition (EMT) of lens epithelial cells and accelerates the healing of corneal tissue after ocular burns (Saika et al. 2005). Transgenic mice expressing Smad7 in the skin show severe epithelial abnormalities, including epidermal hyperplasia and aberrant morphogenesis of hair follicles (He et al. 2002).

cells induces Smad7 expression in a STAT1-dependent manner, leading to sustained T_H1-induced tissue injury (Monteleone et al. 2004c).

High-dose radiation often induces oral mucositis, accompanied by excessive inflammation and epithelial ablation. Transgenic mice overexpressing Smad7 in keratinocytes are resistant to radiation-induced oral mucositis (Han et al. 2013). Smad7 suppresses inflammation through inhibition of the NF-κB pathway and enhances keratinocyte migration through derepression of Rac1 expression. Rac1 expression is down-regulated by TGF-β signaling in the presence of CtBP. Notably, Smad7 protein fused to a cell-permeable tag (Tat) shows therapeutic, as well as prophylactic effects on radiation-induced oral mucositis when topically applied to oral mucosa in mice (Han et al. 2013). In wounded skin, Smad7 is up-regulated in migrating keratinocytes and proliferative fibroblasts, accelerating wound healing and remodeling (Han et al. 2011).

Cancer

Decreased sensitivity to TGF-β-induced growth inhibition because of Smad7 overexpression may aid in the progression of some tumors. Both Smad7 and Smad6 have been shown to be overexpressed in pancreatic cancer cells and to confer resistance to TGF-β family signaling in these cells (Kleeff et al. 1999a,b). Pancreas-specific expression of Smad7 in mice results in the development of premalignant ductal lesions characterized by pancreatic intraepithelial neoplasia and increased fibrosis (Kuang et al. 2006), suggesting a critical role of up-regulated Smad7 expression in pancreas carcinogenesis. Increased expression of Smad7 correlates with poor prognosis for certain types of cancer, including hepatocellular carcinoma and gastric cancer (Kim et al. 2004b; Park et al. 2004). In addition, *SMAD7* copy number and patient survival correlate inversely in colorectal cancer (Boulay et al. 2003). Furthermore, single nucleotide polymorphisms in *SMAD7* are associated with increased risk of colorectal cancer (Broderick et al. 2007; Slattery et al. 2010). Although these polymorphisms do not affect the coding sequence of Smad7, they may result in decreased mRNA expression (Pittman et al. 2009).

UV irradiation may contribute to the progression of squamous cell carcinomas as a result of Smad7-mediated suppression of TGF-β signaling (Quan et al. 2005). The expression of Smad7 and GADD34 is up-regulated by UV irradiation, and the GADD34–PP1c complex cooperates with Smad7 in the inhibition of TGF-β signaling by promoting receptor dephosphorylation (Shi et al. 2004). Thus, the Smad7–GADD34–PP1c complex may induce the proliferation and hyperplasia of keratinocytes and reduce extracellular matrix deposition and premature skin aging, leading to the progression of cancer.

Smad7 has been showed to play a role in the transformation of keratinocytes. Overexpression of Smad7 alone results in facilitated proliferation and the prevention of differentiation of mouse keratinocytes, but fails to induce tumor formation. Cells manipulated to express v-ras^{Ha} or v-ras^{Ha} and *Smad6* form benign papilloma in vivo, but those coexpressing v-ras^{Ha} and *Smad7* rapidly progress to squamous cell carcinoma (Liu et al. 2003). In addition, TGF-β signaling is suppressed and the production of EGF family growth factors, including TGF-α, heparin binding (HB)-EGF, or amphiregulin, is induced in keratinocytes expressing v-ras^{Ha} and *Smad7*. Thus, Smad7 may cooperate with v-ras^{Ha} in the rapid progression of keratinocytes from benign papilloma to malignant squamous carcinoma by preventing TGF-β signaling and enhancing EGFR signaling.

Although perturbations in TGF-β signaling result in the transformation of normal cells, TGF-β signaling also facilitates the invasion by and metastasis of some advanced cancers. Using the JygMC(A) mouse breast cancer cell line, which spontaneously metastasizes to the lung and liver after subcutaneous inoculation in nude mice, systemic administration of an adenovirus expressing Smad7 was shown to prevent metastasis to the lung and liver and prolonged mean survival (Azuma et al. 2005). Smad7 directly affects the cancer cells to inhibit EMT and prevent metastasis. Thus, the blockade of TGF-β signaling by Smad7 may provide new

therapeutic strategies for preventing metastasis in patients with advanced cancers.

CONCLUSION AND PERSPECTIVES

I-Smads are now known to regulate both Smad and non-Smad pathways of TGF-β family signaling through multiple mechanisms. In addition, recent studies have suggested that I-Smads are also involved in the regulation of other signaling pathways. Although it is well established that Smad7, but not Smad6, effectively inhibits TGF-β signaling, how these functional differences arise remains unclear. Because I-Smads are implicated in the development of certain clinical diseases, it is important to elucidate the molecular mechanisms by which I-Smads inhibit TGF-β family signaling. Recent progress in the field have revealed that the functions of I-Smads are tightly regulated by various enzymes, including ubiquitin ligases, acetyltransferases, deacetylase, and methyl transferase. Elucidating the functional roles of these regulators in vivo will be important. As aberrant I-Smad expression has been suggested to play roles in various diseases, it will also be important to determine how the expression levels of I-Smad proteins are controlled in these diseases. Moreover, I-Smads play crucial roles in fine-tuning the magnitude of TGF-β family signaling. Thus, defining the regulatory mechanisms of I-Smad function may aid in understanding how TGF-β family signaling coordinates the growth, differentiation, and morphogenesis of various cells and tissues in physiological and pathological conditions.

Cold

ACKNOWLEDGMENTS

This manuscript is a substantially updated version of a work by K. Miyazono (2008).

REFERENCES

Afrakhte M, Morén A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P. 1998. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. *Biochem Biophys Res Commun* **249:** 505–511.

Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M. 2004. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. *Cancer Res* **64:** 3599–3606.

Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. 2004. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. *J Clin Invest* **113:** 253–264.

Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, et al. 2005. Smad7 inhibits metastasis of mouse breast cancer by direct action on cancer cells. *J Natl Cancer Inst* **97:** 1734–1746.

Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, et al. 2000. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. *Nature* **403:** 211–216.

Bai S, Cao X. 2002. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-β signaling. *J Biol Chem* **277:** 4176–4182.

Bai S, Shi X, Yang X, Cao X. 2000. Smad6 as a transcriptional corepressor. *J Biol Chem* **275:** 8267–8270.

Bai Y, Yang C, Hu K, Elly C, Liu YC. 2004. Itch E3 ligase-mediated regulation of TGF-β signaling by modulating Smad2 phosphorylation. *Mol Cell* **15:** 825–831.

Benchabane H, Wrana JL. 2003. GATA- and Smad1-dependent enhancers in the Smad7 gene differentially interpret bone morphogenetic protein concentrations. *Mol Cell Biol* **23:** 6646–6661.

Beppu H. 2013. Smad7-modified alleles by various gene-targeting strategies. *J Biochem* **153:** 399–401.

Berg DT, Myers LJ, Richardson MA, Sandusky G, Grinnell BW. 2005. Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-β-dependent upregulation of transforming growth factor-β. *J Biol Chem* **280:** 14943–14947.

Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Böttinger EP. 2000. A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/RelA. *Genes Dev* **14:** 187–197.

Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C. 2003. SMAD7 is a prognostic marker in patients with colorectal cancer. *Int J Cancer* **104:** 446–449.

Braunger BM, Pielmeier S, Demmer C, Landstorfer V, Kawall D, Abramov N, Leibinger M, Kleiter I, Fischer D, Jägle H, et al. 2013. TGF-β signaling protects retinal neurons from programmed cell death during the development of the mammalian eye. *J Neurosci* **33:** 14246–14258.

Briones-Orta MA, Sosa-Garrocho M, Moreno-Alvarez P, Fonseca-Sánchez MA, Macías-Silva M. 2006. SnoN corepressor binds and represses *smad7* gene promoter. *Biochem Biophys Res Commun* **341:** 889–894.

Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, et al. 2007. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. *Nat Genet* **39:** 1315–1317.

Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R. 2000. Efficient TGF-β induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad pro-

teins on the mouse Smad7 promoter. *J Biol Chem* **275:** 29023–29030.

Chen Q, Chen H, Zheng D, Kuang C, Fang H, Zou B, Zhu W, Bu G, Jin T, Wang Z, et al. 2009. Smad7 is required for the development and function of the heart. *J Biol Chem* **284:** 292–300.

Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, Lan HY. 2011. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. *Diabetes* **60:** 590–601.

Choi KC, Lee YS, Lim S, Choi HK, Lee CH, Lee EK, Hong S, Kim IH, Kim SJ, Park SH. 2006. Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. *Nat Immunol* **7:** 1057–1065.

Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. 2009. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. *Nephrol Dial Transplant* **24:** 1143–1154.

Cohen TV, Kollias HD, Liu N, Ward CW, Wagner KR. 2015. Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. *J Physiol* **593:** 2479–2497.

Datta PK, Moses HL. 2000. STRAP and Smad7 synergize in the inhibition of transforming growth factor β signaling. *Mol Cell Biol* **20:** 3157–3167.

Davis BN, Hilyard AC, Lagna G, Hata A. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. *Nature* **454:** 56–61.

Denissova NG, Liu F. 2004. Repression of endogenous Smad7 by Ski. *J Biol Chem* **279:** 28143–28148.

Denissova NG, Pouponnot C, Long J, He D, Liu F. 2000. Transforming growth factor β-inducible independent binding of SMAD to the Smad7 promoter. *Proc Natl Acad Sci* **97:** 6397–6402.

Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. 2001. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. *J Biol Chem* **276:** 12477–12480.

Edlund S, Bu S, Schuster N, Aspenström P, Heuchel R, Heldin NE, ten Dijke P, Heldin CH, Landström M. 2003. Transforming growth factor-β1 (TGF-β)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. *Mol Biol Cell* **14:** 529–544.

Edlund S, Landström M, Heldin CH, Aspenström P. 2004. Smad7 is required for TGF-β-induced activation of the small GTPase Cdc42. *J Cell Sci* **117:** 1835–1847.

Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, Landström M. 2005. Interaction between Smad7 and β-catenin: Importance for transforming growth factor β-induced apoptosis. *Mol Cell Biol* **25:** 1475–1488.

Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, et al. 2012. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. *Nat Med* **18:** 429–435.

El-Gohary Y, Tulachan S, Guo P, Welsh C, Wiersch J, Prasadan K, Paredes J, Shiota C, Xiao X, Wada Y, et al. 2013. Smad signaling pathways regulate pancreatic endocrine development. *Dev Biol* **378:** 83–93.

El-Gohary Y, Tulachan S, Wiersch J, Guo P, Welsh C, Prasadan K, Paredes J, Shiota C, Xiao X, Wada Y, et al. 2014. A Smad signaling network regulates islet cell proliferation. *Diabetes* **63:** 224–236.

Episkopou V, Arkell R, Timmons PM, Walsh JJ, Andrew RL, Swan D. 2001. Induction of the mammalian node requires Arkadia function in the extraembryonic lineages. *Nature* **410:** 825–830.

Estrada KD, Retting KN, Chin AM, Lyons KM. 2011. Smad6 is essential to limit BMP signaling during cartilage development. *J Bone Miner Res* **26:** 2498–2510.

Estrada KD, Wang W, Retting KN, Chien CT, Elkhoury FF, Heuchel R, Lyons KM. 2013. Smad7 regulates terminal maturation of chondrocytes in the growth plate. *Dev Biol* **15:** 375–384.

Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. 2004. Cutting edge: TGF-β induces a regulatory phenotype in $CD4^+CD25^-$ T cells through Foxp3 induction and down-regulation of Smad7. *J Immunol* **172:** 5149–5153.

Ferrigno O, Lallemand F, Verrecchia F, L'Hoste S, Camonis J, Atfi A, Mauviel A. 2002. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling. *Oncogene* **21:** 4879–4884.

Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, et al. 2004. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. *Proc Natl Acad Sci* **101:** 8687–8692.

Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr, et al. 2000. A role for Smad6 in development and homeostasis of the cardiovascular system. *Nat Genet* **24:** 171–174.

Glesne D, Huberman E. 2006. Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation. *Oncogene* **25:** 4086–4098.

Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K. 2007. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. *J Biol Chem* **282:** 20603–20611.

Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. *Mol Cell* **12:** 817–828.

Grönroos E, Hellman U, Heldin CH, Ericsson J. 2002. Control of Smad7 stability by competition between acetylation and ubiquitination. *Mol Cell* **10:** 483–493.

Gruber T, Hinterleitner R, Hermann-Kleiter N, Meisel M, Kleiter I, Wang CM, Viola A, Pfeifhofer-Obermair C, Baier G. 2013. Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells. *J Mol Cell Biol* **5:** 358–368.

Hamzavi J, Ehnert S, Godoy P, Ciuclan L, Weng H, Mertens PR, Heuchel R, Dooley S. 2008. Disruption of the Smad7 gene enhances CCl_4-dependent liver damage and fibrogenesis in mice. *J Cell Mol Med* **12:** 2130–2144.

Han G, Li F, Ten Dijke P, Wang XJ. 2011. Temporal Smad7 transgene induction in mouse epidermis accelerates skin wound healing. *Am J Pathol* **179:** 1768–1779.

Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, et al. 2013. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. *Nat Med* **19:** 421–428.

Hanyu A, Ishidou Y, Ebisawa T, Shimanuki T, Imamura T, Miyazono K. 2001. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. *J Cell Biol* **155:** 1017–1027.

Hata A, Lo RS, Wotton D, Lagna G, Massagué J. 1997. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. *Nature* **388:** 87–93.

Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A. 1998. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. *Genes Dev* **12:** 186–197.

Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J. 2000. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. *Cell* **100:** 229–240.

Ha Thi HT, Kim HY, Choi SW, Kang JM, Kim SJ, Hong S. 2015. Smad7 modulates epidermal growth factor receptor turnover through sequestration of c-Cbl. *Mol Cell Biol* **35:** 2841–2850.

Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, et al. 1997. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. *Cell* **89:** 1165–1173.

He W, Li AG, Wang D, Han S, Zheng B, Goumans MJ, Ten Dijke P, Wang XJ. 2002. Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. *EMBO J* **21:** 2580–2590.

Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK, Park SH, Wang XJ, Kim SJ. 2007. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. *Nat Immunol* **8:** 504–513.

Hong S, Kim HY, Kim J, Ha HT, Kim YM, Bae E, Kim TH, Lee KC, Kim SJ. 2013. Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. *J Biol Chem* **288:** 3560–3570.

Horiki M, Imamura T, Okamoto M, Hayashi M, Murai J, Myoui A, Ochi T, Miyazono K, Yoshikawa H, Tsumaki N. 2004. Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. *J Cell Biol* **165:** 433–445.

Hua X, Miller ZA, Benchabane H, Wrana JL, Lodish HF. 2000. Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-β-induced transcription of the Smad7 gene. *J Biol Chem* **275:** 33205–33208.

Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, et al. 2002. IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. *J Clin Invest* **109:** 931–937.

Ibarrola N, Kratchmarova I, Nakajima D, Schiemann WP, Moustakas A, Pandey A, Mann M. 2004. Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor β signaling. *BMC Cell Biol* **5:** 2.

Ichijo T, Voutetakis A, Cotrim AP, Bhattachryya N, Fujii M, Chrousos GP, Kino T. 2005. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: Potential clinical implications. *J Biol Chem* **280:** 42067–42077.

Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. 1997. Smad6 inhibits signalling by the TGF-β superfamily. *Nature* **389:** 622–626.

Inamitsu M, Itoh S, Hellman U, ten Dijke P, Kato M. 2006. Methylation of Smad6 by protein arginine *N*-methyltransferase 1. *FEBS Lett* **580:** 6603–6611.

Inoue H, Imamura T, Ishidou Y, Takase M, Udagawa Y, Oka Y, Tsuneizumi K, Tabata T, Miyazono K, Kawabata M. 1998. Interplay of signal mediators of decapentaplegic (Dpp): Molecular characterization of mothers against dpp, Medea, and daughters against dpp. *Mol Biol Cell* **9:** 2145–2156.

Ishida W, Hamamoto T, Kusanagi K, Yagi K, Kawabata M,

Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. *Mol Cell* **6:** 1365–1375.

Kim BC, Lee HJ, Park SH, Lee SR, Karpova TS, McNally JG, Felici A, Lee DK, Kim SJ. 2004a. Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor β signaling by binding to Smad7 and promoting its degradation. *Mol Cell Biol* **24:** 2251–2262.

Kim YH, Lee HS, Lee HJ, Hur K, Kim WH, Bang YJ, Kim SJ, Lee KU, Choe KJ, Yang HK. 2004b. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. *Ann Oncol* **15:** 574–580.

Kim YC, Kim KK, Shevach EM. 2010. Simvastatin induces $Foxp3^+$ T regulatory cells by modulation of transforming growth factor-β signal transduction. *Immunology* **130:** 484–493.

Kim TA, Kang JM, Hyun JS, Lee B, Kim SJ, Yang ES, Hong S, Lee HJ, Fujii M, Niederhuber JE, et al. 2014. The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-β. *J Cell Sci* **127:** 411–421.

Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M. 1999a. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. *Oncogene* **18:** 5363–5372.

Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M. 1999b. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. *Biochem Biophys Res Commun* **255:** 268–273.

Kleiter I, Song J, Lukas D, Hasan M, Neumann B, Croxford AL, Pedré X, Hövelmeyer N, Yogev N, Mildner A, et al. 2010. Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. *Brain* **133:** 1067–1081.

Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, Ebina M, Nukiwa T, Miyazawa K, Imamura T, et al. 2003. Arkadia amplifies TGF-β superfamily signalling through degradation of Smad7. *EMBO J* **22:** 6458–6470.

Koinuma D, Shinozaki M, Nagano Y, Ikushima H, Horiguchi K, Goto K, Chano T, Saitoh M, Imamura T, Miyazono K, et al. 2011. RB1CC1 protein positively regulates transforming growth factor-β signaling through the modulation of Arkadia E3 ubiquitin ligase activity. *J Biol Chem* **286:** 32502–32512.

Kollias HD, Perry RL, Miyake T, Aziz A, McDermott JC. 2006. Smad7 promotes and enhances skeletal muscle differentiation. *Mol Cell Biol* **26:** 6248–6260.

Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K. 2004. Negative regulation of transforming growth factor-β (TGF-β) signaling by WW domain-containing protein 1 (WWP1). *Oncogene* **23:** 6914–6923.

Kowanetz M, Lönn P, Vanlandewijck M, Kowanetz K, Heldin CH, Moustakas A. 2008. TGFβ induces SIK to negatively regulate type I receptor kinase signaling. *J Cell Biol* **182:** 655–662.

Krampert M, Chirasani SR, Wachs FP, Aigner R, Bogdahn U, Yingling JM, Heldin CH, Aigner L, Heuchel R. 2010. Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor β- and bone morphogenetic protein-independent manner. *Mol Cell Biol* **30:** 3685–3694.

Krikos A, Laherty CD, Dixit VM. 1992. Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements. *J Biol Chem* **267:** 17971–17976.

Krishnan P, King MW, Neff AW, Sandusky GE, Bierman KL, Grinnell B, Smith RC. 2001. Human truncated Smad 6 (Smad 6s) inhibits the BMP pathway in *Xenopus laevis*. *Dev Growth Differ* **43:** 115–132.

Kruithof BP, Duim SN, Moerkamp AT, Goumans MJ. 2012. TGFβ and BMP signaling in cardiac cushion formation: Lessons from mice and chicken. *Differentiation* **84:** 89–102.

Ku M, Howard S, Ni W, Lagna G, Hata A. 2006. OAZ regulates bone morphogenetic protein signaling through Smad6 activation. *J Biol Chem* **281:** 5277–5287.

Kuang C, Xiao Y, Liu X, Stringfield TM, Zhang S, Wang Z, Chen Y. 2006. In vivo disruption of TGF-β signaling by Smad7 leads to premalignant ductal lesions in the pancreas. *Proc Natl Acad Sci* **103:** 1858–1863.

Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, et al. 2007. SIRT1 inhibits transforming growth factor β-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. *J Biol Chem* **282:** 151–158.

Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T. 2005. NEDD4–2 (neural precursor cell expressed, developmentally down-regulated 4–2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor. *Biochem J* **386:** 461–470.

Lallemand F, Mazars A, Prunier C, Bertrand F, Kornprost M, Gallea S, Roman-Roman S, Cherqui G, Atfi A. 2001. Smad7 inhibits the survival nuclear factor κB and potentiates apoptosis in epithelial cells. *Oncogene* **20:** 879–884.

Lallemand F, Seo SR, Ferrand N, Pessah M, L'hoste S, Rawadi G, Romain-Romain S, Camonis J, Atfi A. 2005. AIP4 restricts TGF-β signaling through an ubiquitination-independent mechanism. *J Biol Chem* **280:** 27645–27653.

Landström M, Heldin NE, Bu S, Hermansson A, Itoh S, ten Dijke P, Heldin CH. 2000. Smad7 mediates apoptosis induced by transforming growth factor β in prostatic carcinoma cells. *Curr Biol* **10:** 535–538.

Lee SJ. 2004. Regulation of muscle mass by myostatin. *Annu Rev Cell Dev Biol* **20:** 61–86.

Lee YS, Park JS, Kim JH, Jung SM, Lee JY, Kim SJ, Park SH. 2011. Smad6-specific recruitment of Smurf E3 ligases mediates TGF-β1-induced degradation of MyD88 in TLR4 signalling. *Nat Commun* **2:** 460.

Lee YS, Park JS, Jung SM, Kim SD, Kim JH, Lee JY, Jung KC, Mamura M, Lee S, Kim SJ, et al. 2015. Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide. *EMBO Mol Med* **7:** 577–592.

Le Scolan E, Zhu Q, Wang L, Bandyopadhyay A, Javelaud D, Mauviel A, Sun L, Luo K. 2008. Transforming growth factor-β suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. *Cancer Res* **68:** 3277–3285.

Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. 2007. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. *Mol Cell Biol* **27:** 6068–6083.

Li H, Seth A. 2004. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. *Oncogene* **23:** 1801–1808.

Li R, Rosendahl A, Brodin G, Cheng AM, Ahgren A, Sundquist C, Kulkarni S, Pawson T, Heldin CH, Heuchel RL. 2006. Deletion of exon I of SMAD7 in mice results in altered B cell responses. *J Immunol* **176:** 6777–6784.

Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J, Xiong W, Mi J. 2013. MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. *Sci Rep* **10:** 1038.

Lin X, Liang M, Feng XH. 2000. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. *J Biol Chem* **275:** 36818–36822.

Lin X, Liang YY, Sun B, Liang M, Shi Y, Brunicardi FC, Shi Y, Feng XH. 2003. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. *Mol Cell Biol* **23:** 9081–9093.

Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A. 2003. Smad7 but not Smad6 cooperates with oncogenic *ras* to cause malignant conversion in a mouse model for squamous cell carcinoma. *Cancer Res* **63:** 7760–7768.

Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan SC, et al. 2006. Axin is a scaffold protein in TGF-β signaling that promotes degradation of Smad7 by Arkadia. *EMBO J* **25:** 1646–1658.

Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. 2010. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. *J Exp Med* **207:** 1589–1597.

Liu GX, Li YQ, Huang XR, Wei L, Chen HY, Shi YJ, Heuchel RL, Lan HY. 2013. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NFκB-dependent mechanisms in mice. *PLoS ONE* **8:** e53573.

Lönn P, Vanlandewijck M, Raja E, Kowanetz M, Watanabe Y, Kowanetz K, Vasilaki E, Heldin CH, Moustakas A. 2012. Transcriptional induction of salt-inducible kinase 1 by transforming growth factor β leads to negative regulation of type I receptor signaling in cooperation with the Smurf2 ubiquitin ligase. *J Biol Chem* **287:** 12867–12878.

Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. 2004. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. *EMBO J* **23:** 552–563.

Mazars A, Lallemand F, Prunier C, Marais J, Ferrand N, Pessah M, Cherqui G, Atfi A. 2001. Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. *J Biol Chem* **276:** 36797–36803.

Meno C, Gritsman K, Ohishi S, Ohfuji Y, Heckscher E, Mochida K, Shimono A, Kondoh H, Talbot WS, Robertson EJ, et al. 1999. Mouse Lefty2 and zebrafish antivin are feedback inhibitors of nodal signaling during vertebrate gastrulation. *Mol Cell* **4:** 287–298.

Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP, Vortkamp A. 2001. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. *Development* **128:** 4523–4534.

Miyake T, Alli NS, McDermott JC. 2010. Nuclear function of Smad7 promotes myogenesis. *Mol Cell Biol* **30:** 722–735.

Miyazono K. 2000. Positive and negative regulation of TGF-β signaling. *J Cell Sci* **113:** 1101–1109.

Miyazono K. 2008. Regulation of TGF-β family signaling by inhibitory Smads. In *The TGF-β family* (ed. Derynck R, Miyazono K), pp. 363–387. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Mochizuki T, Miyazaki H, Hara T, Furuya T, Imamura T, Watabe T, Miyazono K. 2004. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-β superfamily signaling. *J Biol Chem* **279:** 31568–31574.

Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. 2001. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. *J Clin Invest* **108:** 601–609.

Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M, Del Vecchio Blanco G, Tersigni R, Alessandroni L, Mann D, et al. 2004a. A failure of transforming growth factor-β1 negative regulation maintains sustained NF-κB activation in gut inflammation. *J Biol Chem* **279:** 3925–3932.

Monteleone G, Pallone F, MacDonald TT. 2004b. Smad7 in TGF-β-mediated negative regulation of gut inflammation. *Trends Immunol* **25:** 513–517.

Monteleone G, Del Vecchio Blanco G, Palmieri G, Vavassori P, Monteleone I, Colantoni A, Battista S, Spagnoli LG, Romano M, Borrelli M, et al. 2004c. Induction and regulation of Smad7 in the gastric mucosa of patients with *Helicobacter pylori* infection. *Gastroenterology* **126:** 674–682.

Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, et al. 2015. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med* **372:** 1104–1113.

Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. 2003. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. *Mol Biol Cell* **14:** 2809–2817.

Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, Sase H, Yuki K, Isogaya K, Saitoh M, Imamura T, et al. 2007. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-β signaling. *J Biol Chem* **282:** 20492–20501.

Nagarajan RP, Zhang J, Li W, Chen Y. 1999. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. *J Biol Chem* **274:** 33412–33418.

Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al. 1997. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. *Nature* **389:** 631–635.

Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I. 1999. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. *J Clin Invest* **104:** 5–11.

Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, Iwamoto I. 2000. Blockade of transforming growth factor β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. *J Exp Med* **192:** 151–158.

Cold Spring Harbor Perspectives in Biology
www.cshperspectives.org

Nakayama T, Gardner H, Berg LK, Christian JL. 1998a. Smad6 functions as an intracellular antagonist of some TGF-β family members during *Xenopus* embryogenesis. *Genes Cells* **3:** 387–394.

Nakayama T, Snyder MA, Grewal SS, Tsuneizumi K, Tabata T, Christian JL. 1998b. Xenopus Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. *Development* **125:** 857–867.

Nakayama T, Berg LK, Christian JL. 2001. Dissection of inhibitory Smad proteins: Both N- and C-terminal domains are necessary for full activities of *Xenopus* Smad6 and Smad7. *Mech Dev* **100:** 251–262.

Niederlander C, Walsh JJ, Episkopou V, Jones CM. 2001. Arkadia enhances nodal-related signalling to induce mesendoderm. *Nature* **410:** 830–834.

Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. 1999. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature* **398:** 252–256.

Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavsak P, Rasmussen RK, Seet BT, Sicheri F, Wrana JL. 2005. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. *Mol Cell* **19:** 297–308.

Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C. 1999. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. *Nature* **401:** 480–485.

Padgett RW, Patterson GI. 2006. *C. elegans* TGF-β signaling pathways. In *Smad signal transduction* (ed. ten Dijke P, Heldin CH), pp. 37–53. Springer, Amsterdam, The Netherlands.

Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, et al. 2014. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. *Nat Commun* **5:** 2977.

Park YN, Chae KJ, Oh BK, Choi J, Choi KS, Park C. 2004. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: Resistance mechanism to transforming growth factor-β. *Hepatogastroenterology* **51:** 396–400.

Patil S, Wildey GM, Brown TL, Choy L, Derynck R, Howe PH. 2000. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-β-induced growth inhibition and apoptosis. *J Biol Chem* **275:** 38363–38370.

Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, Morreau H, Sullivan K, Fielding S, Twiss P, et al. 2009. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. *Genome Res* **19:** 987–993.

Pulaski L, Landström M, Heldin CH, Souchelnytskyi S. 2001. Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-β-dependent signaling but affects Smad7-dependent transcriptional activation. *J Biol Chem* **276:** 14344–14349.

Quan T, He T, Voorhees JJ, Fisher GJ. 2005. Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. *J Biol Chem* **280:** 8079–8085.

Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW, et al. 2005. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. *Am J Pathol* **166:** 1405–1418.

Sandusky G, Berg DT, Richardson MA, Myers L, Grinnell BW. 2002. Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads. *J Biol Chem* **277:** 49815–49819.

Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Böttinger EP. 2001. Apoptosis in podocytes induced by TGF-β and Smad7. *J Clin Invest* **108:** 807–816.

Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, Atfi A. 2004. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. *EMBO J* **23:** 3780–3792.

Seong HA, Jung H, Ha H. 2010. Murine protein serine/threonine kinase 38 stimulates TGF-β signaling in a kinase-dependent manner via direct phosphorylation of Smad proteins. *J Biol Chem* **285:** 30959–30970.

Shen R, Chen M, Wang YJ, Kaneki H, Xing L, O'Keefe RJ, Chen D. 2006. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. *J Biol Chem* **281:** 3569–3576.

Shi Y, Massagué J. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. *Cell* **113:** 685–700.

Shi W, Sun C, He B, Xiong W, Shi X, Yao D, Cao X. 2004. GADD34-PP1c recruited by Smad7 dephosphorylates TGFβ type I receptor. *J Cell Biol* **164:** 291–300.

Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. *Genes Dev* **19:** 2668–2681.

Simonsson M, Heldin CH, Ericsson J, Grönroos E. 2005. The balance between acetylation and deacetylation controls Smad7 stability. *J Biol Chem* **280:** 21797–21803.

Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, Duggan D, Potter JD, Peters U. 2010. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. *Cancer Res* **70:** 1479–1485.

Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. 2012. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. *Oncogene* **31:** 5162–5171.

Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landström M. 2008. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. *Nat Cell Biol* **10:** 1199–1207.

Souchelnytskyi S, Nakayama T, Nakao A, Morén A, Heldin CH, Christian JL, ten Dijke P. 1998. Physical and functional interaction of murine and *Xenopus* Smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. *J Biol Chem* **273:** 25364–25370.

Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, Miyazono K. 2002. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. *J Biol Chem* **277:** 39919–39925.

Tajima Y, Goto K, Yoshida M, Shinomiya K, Sekimoto T, Yoneda Y, Miyazono K, Imamura T. 2003. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-β signaling by Smad7. *J Biol Chem* **278:** 10716–10721.

Tan HL, Glen E, Töpf A, Hall D, O'Sullivan JJ, Sneddon L, Wren C, Avery P, Lewis RJ, ten Dijke P, et al. 2012. Non-synonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. *Hum Mutat* **33:** 720–727.

Terada Y, Hanada S, Nakao A, Kuwahara M, Sasaki S, Marumo F. 2002. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. *Kidney Int* **61:** 94–98.

Thisse C, Thisse B. 1999. Antivin, a novel and divergent member of the TGFβ superfamily, negatively regulates mesoderm induction. *Development* **126:** 229–240.

Tojo M, Takebe A, Takahashi S, Tanaka K, Imamura T, Miyazono K, Chiba T. 2012. Smad7-deficient mice show growth retardation with reduced viability. *J Biochem* **151:** 621–631.

Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, Feeley R, Gimeno CJ, Woolf EA, Tayber O, et al. 1997. Vascular MADs: Two novel MAD-related genes selectively inducible by flow in human vascular endothelium. *Proc Natl Acad Sci* **94:** 9314–9319.

Tsubakihara Y, Hikita A, Yamamoto S, Matsushita S, Matsushita N, Oshima Y, Miyazawa K, Imamura T. 2015. Arkadia enhances BMP signaling through ubiquitylation and degradation of Smad6. *J Biochem* **158:** 61–71.

Tsuneizumi K, Nakayama T, Kamoshida Y, Kornberg TB, Christian JL, Tabata T. 1997. Daughters against *dpp* modulates *dpp* organizing activity in *Drosophila* wing development. *Nature* **389:** 627–631.

Ulloa L, Doody J, Massagué J. 1999. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. *Nature* **397:** 710–713.

Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F. 2002. Functions of transforming growth factor-β family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. *J Biol Chem* **277:** 33545–33558.

Valdimarsdottir G, Goumans MJ, Itoh F, Itoh S, Heldin CH, ten Dijke P. 2006. Smad7 and protein phosphatase 1α are critical determinants in the duration of TGF-β/ALK1 signaling in endothelial cells. *BMC Cell Biol* **7:** 16.

Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, et al. 1988. Chemical and biological characterization of the inhibin family of protein hormones. *Recent Prog Horm Res* **44:** 1–34.

Wachs FP, Winner B, Couillard-Despres S, Schiller T, Aigner R, Winkler J, Bogdahn U, Aigner L. 2006. Transforming growth factor-β1 is a negative modulator of adult neurogenesis. *J Neuropathol Exp Neurol* **65:** 358–370.

Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N, Cao X. 2002. Jab1 antagonizes TGF-β signaling by inducing Smad4 degradation. *EMBO Rep* **3:** 171–176.

Wang H, Song K, Sponseller TL, Danielpour D. 2005. Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. *J Biol Chem* **280:** 5154–5162.

Wang H, Song K, Krebs TL, Yang J, Danielpour D. 2008. Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. *Oncogene* **27:** 6791–6805.

Wang J, Zhao J, Chu ES, Mok MT, Go MY, Man K, Heuchel R, Lan HY, Chang Z, Sung JJ, et al. 2013. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. *J Pathol* **230:** 441–452.

Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Heuchel R, Yan BP, Yu CM, Lan HY. 2013. Deficiency of Smad7 enhances cardiac remodeling induced by angiotensin II infusion in a mouse model of hypertension. *PLoS ONE* **8:** e70195.

Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. 2006. Cutting edge: Deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-β sensitivity in vitro and in vivo. *J Immunol* **176:** 1316–1320.

Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, et al. 2004. Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor-β signaling by halofuginone. *J Biol Chem* **279:** 15167–15176.

Xia H, Ooi LL, Hui KM. 2013. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. *Hepatology* **58:** 629–641.

Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, Song Z, El-Gohary Y, Prasadan K, Shiota C, et al. 2014. M2 macrophages promote β-cell proliferation by up-regulation of SMAD7. *Proc Natl Acad Sci* **111:** 1211–1220.

Xie Z, Chen Y, Li Z, Bai G, Zhu Y, Yan R, Tan F, Chen YG, Guillemot F, Li L, et al. 2011. Smad6 promotes neuronal differentiation in the intermediate zone of the dorsal neural tube by inhibition of the Wnt/β-catenin pathway. *Proc Natl Acad Sci* **108:** 12119–12124.

Xu J, Wang AH, Oses-Prieto J, Makhijani K, Katsuno Y, Pei M, Yan L, Zheng YG, Burlingame A, Brückner K, et al. 2013. Arginine methylation initiates BMP-induced Smad signaling. *Mol Cell* **51:** 5–19.

Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. *Science* **270:** 2008–2011.

Yamamura Y, Hua X, Bergelson S, Lodish HF. 2000. Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis. *J Biol Chem* **275:** 36295–36302.

Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. 2008. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. *Mol Cell* **31:** 918–924.

Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, Chen YG. 2009. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-β signaling. *J Biol Chem* **284:** 30097–30104.

Yan X, Zhang J, Pan L, Wang P, Xue H, Zhang L, Gao X, Zhao X, Ning Y, Chen YG. 2011. TSC-22 promotes transforming growth factor β-mediated cardiac myofibroblast dif-

ferentiation by antagonizing Smad7 activity. *Mol Cell Biol* **31:** 3700–3709.

Yan XH, Pan J, Xiong WW, Cheng MZ, Sun YY, Zhang SP, Chen YG. 2014. Yin Yang 1 (YY1) synergizes with Smad7 to inhibit TGF-β signaling in the nucleus. *Sci China Life Sci* **57:** 128–136.

Yan X, Liao H, Cheng M, Shi X, Lin X, Feng XH, Chen YG. 2016. Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-β (TGF-β)/Smad signaling. *J Biol Chem* **291:** 382–392.

Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, et al. 2000. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. *Cell* **103:** 1085–1097.

Yoshida Y, von Bubnoff A, Ikematsu N, Blitz IL, Tsuzuku JK, Yoshida EH, Umemori H, Miyazono K, Yamamoto T, Cho KW. 2003. Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signaling. *Mech Dev* **120:** 629–637.

Zhang YE. 2009. Non-Smad pathways in TGF-β signaling. *Cell Res* **19:** 128–139.

Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. 2001. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. *Proc Natl Acad Sci* **98:** 97497–97499.

Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng XH, Meng A, Chen YG. 2007. Smad7 antagonizes transforming growth factor β signaling in the nucleus by interfering with functional Smad-DNA complex formation. *Mol Cell Biol* **27:** 4488–4499.

Zhang L, Huang H, Zhou F, Schimmel J, Pardo CG, Zhang T, Barakat TS, Sheppard KA, Mickanin C, Porter JA, et al. 2012. RNF12 controls embryonic stem cell fate and morphogenesis in zebrafish embryos by targeting Smad7 for degradation. *Mol Cell* **46:** 650–661.

Zhang R, Huang H, Cao P, Wang Z, Chen Y, Pan Y. 2013a. Sma- and Mad-related protein 7 (Smad7) is required for embryonic eye development in the mouse. *J Biol Chem* **288:** 10275–10285.

Zhang X, Zhang J, Bauer A, Zhang L, Selinger DW, Lu CX, ten Dijke P. 2013b. Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2–230K-mediated monoubiquitination of SMAD6. *EMBO J* **32:** 996–1007.

Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, et al. 2014. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling. *Nat Commun* **5:** 3388.

Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. *Nature* **400:** 687–693.

Zhu L, Wang L, Wang X, Luo X, Yang L, Zhang R, Yin H, Xie D, Pan Y, Chen Y. 2011. Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. *PLoS ONE* **6:** e17415.

Zhu L, Wang L, Luo X, Zhang Y, Ding Q, Jiang X, Wang X, Pan Y, Chen Y. 2012. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-β signaling pathway. *J Biol Chem* **287:** 39653–39663.



Regulation of TGF-β Family Signaling by Inhibitory Smads

Keiji Miyazawa and Kohei Miyazono

Cold Spring Harb Perspect Biol 2017; doi: 10.1101/cshperspect.a022095 originally published online December 5, 2016